Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics has secured a CA$20 million investment from RA Capital Management to support the advancement of its lead program MDNA11 and other preclinical superkine immunotherapies. The non-brokered private placement will strengthen the company’s financial position and extend its cash runway into 2026. This strategic funding highlights RA Capital Management’s confidence in Medicenna’s innovative approach to cancer treatment through engineered cytokines.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
